Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Adma Biologics (ADMA) EPS (Weighted Average and Diluted) (2020 - 2025)

Adma Biologics' EPS (Weighted Average and Diluted) history spans 6 years, with the latest figure at $0.2 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) fell 56.52% year-over-year to $0.2; the TTM value through Dec 2025 reached $0.6, down 26.83%, while the annual FY2025 figure was $0.6, 25.93% down from the prior year.
  • EPS (Weighted Average and Diluted) reached $0.2 in Q4 2025 per ADMA's latest filing, up from $0.15 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.46 in Q4 2024 to a low of -$0.16 in Q1 2021.
  • Average EPS (Weighted Average and Diluted) over 5 years is $0.02, with a median of -$0.03 recorded in 2023.
  • Peak YoY movement for EPS (Weighted Average and Diluted): soared 1400.0% in 2024, then tumbled 56.52% in 2025.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.07 in 2021, then grew by 14.29% to -$0.06 in 2022, then tumbled by 33.33% to -$0.08 in 2023, then skyrocketed by 675.0% to $0.46 in 2024, then crashed by 56.52% to $0.2 in 2025.
  • Per Business Quant, the three most recent readings for ADMA's EPS (Weighted Average and Diluted) are $0.2 (Q4 2025), $0.15 (Q3 2025), and $0.14 (Q2 2025).